CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6276 result(s)

Indacaterol glycopyrronium mometasone furoate (Enerzair Breezhaler)

Last Updated: December 21, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: indacaterol glycopyrronium mometasone furoate
Indications: Indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a medium or high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous 12 months.

  • Brand Name: Enerzair Breezhaler
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0645-000
  • Project Status: Complete
  • Submission Type: Initial

von Willebrand Factor [recombinant] (Vonvendi)

Last Updated: January 21, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: von Willebrand Factor [recombinant]
Indications: ​Indicated for: Treatment and Control of bleeding episodes in adults (age ≥18) diagnosed with von Willebrand Disease (VWD).Perioperative management of bleeding in adults (age ≥18) diagnosed with VWD

  • Brand Name: Vonvendi
  • Manufacturer: Shire Pharma Canada ULC, now part of Takeda
  • Project Number: ST0639-000
  • Project Status: Active
  • Submission Type: Initial

vedolizumab (Entyvio)

Last Updated: January 22, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: vedolizumab
Indications: For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to immunomodulators or a TNFα antagonist; or have had an inadequate response, intolerance, or demonstrated dependence on corticosteroids.

  • Brand Name: Entyvio
  • Manufacturer: Takeda Canada Inc.
  • Project Number: SR0647-000
  • Project Status: Active
  • Submission Type: Initial

ofatumumab (TBC)

Last Updated: December 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: ofatumumab
Indications: For the treatment of Relapsing Multiple Sclerosis (RMS).

  • Brand Name: TBC
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0657-0000
  • Project Status: Active
  • Submission Type: Initial

amifampridine (Ruzurgi)

Last Updated: December 24, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: amifampridine
Indications: Indicated for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 years of age and older.

  • Brand Name: Ruzurgi
  • Manufacturer: Médunik Canada Inc.
  • Project Number: SR0660-000
  • Project Status: Active
  • Submission Type: Initial

ranolazine (Corzyna)

Last Updated: December 21, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: ranolazine
Indications: Indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies, including beta-blockers and calcium channel blockers.

  • Brand Name: Corzyna
  • Manufacturer: KYE Pharmaceuticals Inc.
  • Project Number: SR0655-000
  • Project Status: Active
  • Submission Type: Initial

nintedanib (Ofev)

Last Updated: December 22, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: nintedanib
Indications: Treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as progressive fibrosing ILD)

  • Brand Name: Ofev
  • Manufacturer: Boehringer Ingelheim (Canada) Ltd.
  • Project Number: SR0654-000
  • Project Status: Active
  • Submission Type: Initial

durvalumab (Imfinzi)

Last Updated: December 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: durvalumab
Indications: IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

  • Brand Name: Imfinzi
  • Manufacturer: AstraZeneca Canada Inc.
  • Project Number: PC0234-000
  • Project Status: Active
  • Submission Type: Initial

ozanimod (Zeposia)

Last Updated: December 22, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: ozanimod
Indications: For the treatment of patients with relapsing remitting multiple sclerosis (RRMS) to decrease the frequency of clinical exacerbations.

  • Brand Name: Zeposia
  • Manufacturer: Celgene Inc.
  • Project Number: SR0652-000
  • Project Status: Active
  • Submission Type: Initial

pembrolizumab (Keytruda)

Last Updated: December 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: pembrolizumab
Indications: ​For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)

  • Brand Name: Keytruda
  • Manufacturer: Merck Canada Inc.
  • Project Number: PC0235-000
  • Project Status: Active
  • Submission Type: Initial